Drugs /

atorvastatin

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)

Clinical Trials

View Clinical Trials for atorvastatin

Atorvastatin has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating atorvastatin, 1 is early phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for atorvastatin clinical trials.

Breast carcinoma, breast carcinoma in situ, and invasive breast carcinoma are the most common diseases being investigated in atorvastatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Atorvastatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating atorvastatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
atorvastatin (product), atorvastatin, (betar,deltar)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic acid, atorvastatin (substance), (betar,deltar)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid, 134523-00-5, atorvastatin, liptonorm
NCIT ID [1]:
C61527
SNOMED ID [1]:
F-617DA

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.